Get the Stockscreener App
1.0401
0.94%
-0.0099
Pavmed Inc stock is traded at $1.0401, with a volume of 16,301.
It is down -0.94% in the last 24 hours and down -18.10% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$1.05
Open:
$1.04
24h Volume:
16,301
Relative Volume:
0.27
Market Cap:
$10.65M
Revenue:
$1.52M
Net Income/Loss:
$-70.60M
P/E Ratio:
-1.2382
EPS:
-0.84
Net Cash Flow:
$-57.34M
1W Performance:
-1.88%
1M Performance:
-18.10%
6M Performance:
-49.75%
1Y Performance:
+293.98%
1-Day Range:
$1.033
$1.0918
1-Week Range:
$1.02
$1.11
52-Week Range:
$0.20
$4.44
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
Lucid Diagnostics expands direct contracting for cancer testing - Investing.com
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - StockTitan
Lucid Diagnostics to Participate in Upcoming Investor Conferences - GuruFocus.com
Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test - MSN
Veris Health receives $1.8M NIH grant for cancer care - Mobihealth News
Lucid Diagnostics secures US patent for esophageal cancer test - Investing.com
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - Quantisnow
Lucid Diagnostics stock maintains Buy rating from BTIG - Investing.com India
Lucid Diagnostics stock maintains Buy rating from BTIG By Investing.com - Investing.com South Africa
PAVmed, Veris Health get USD 1.8M NIH grant - Medical Buyer
PAVmed subsidiary receives $1.8 million NIH grant for cancer care By Investing.com - Investing.com South Africa
PAVmed subsidiary receives $1.8 million NIH grant for cancer care - Investing.com India
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - PR Newswire
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PR Newswire
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - StreetInsider.com
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 – Company Announcement - Financial Times
Contrasting enVVeno Medical (NASDAQ:NVNO) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players - Financial Times
Lucid Diagnostics Announces Multiple Presentations at the Upcomi - GuruFocus.com
Lucid Diagnostics Strengthens and Expands Market Access and Dire - GuruFocus.com
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Luci - GuruFocus.com
Pavna Industries Ltd leads gainers in 'B' group - Business Standard
Sound Shore Management Inc. CT Trims Holdings in PVH Corp. (NYSE:PVH) - Defense World
Palantir Skids Despite Winning Army Contract - Baystreet.ca
Palantir Wins Multimillion-Dollar Deal to Expand Maven Smart System to U.S. Army, Air Force, Space Force and - The Bharat Express News
Palantir Wins Deal Worth Multi-Million Dollars To Expand Maven Smart System Across US Army, Air Force, Space Force & Navy - Yahoo Finance
Palantir announces $99.8M contract award by DEVCOM Army Research Laboratory - Seeking Alpha
Hsbc Holdings PLC Boosts Stock Holdings in PDD Holdings Inc. (NASDAQ:PDD) - MarketBeat
SBC Medical Group Holdings and Pono Capital Two Announce Completion of Business Combination and Schedule to Begin Trading on the Nasdaq - Business Wire
PAVmed moves to deconsolidate Lucid Diagnostics - Investing.com India
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements - Seeking Alpha
PAVmed’s Strategic Overhaul to Secure Nasdaq Compliance - TipRanks
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements - PR Newswire
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress - StockTitan
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health – Company Announcement - Financial Times
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - PR Newswire
PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q2 2024 - MSN
Lucid Diagnostics reports high accuracy in esophageal test study By Investing.com - Investing.com Australia
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer - PR Newswire
PAVmed Inc. (NASDAQ:PAVM) Q2 2024 Earnings Call Transcript - Insider Monkey
PAVmed (NASDAQ:PAVM) Stock Price Passes Below 50-Day Moving Average of $0.90 - Defense World
Earnings call: PAVmed reports growth and strategic moves in Q2 2024 - Investing.com Australia
Lucid Diagnostics Launches New Corporate Website - Longview News-Journal
PAVmed Inc (PAVM) Q2 2024 Earnings Call Transcript Highlights: R - GuruFocus.com
PAVmed Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
PAVmed’s EsoGuard revenue for Q2 2024 stands at USD 1.0M - Medical Buyer
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):